Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Sponsor
Beijing Sanbo Brain Hospital
Study ID
NCT04501705
Status
Recruiting
Apply to this trial

Conditions

  • Recurrent Atypical/malignant Meningioma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Apatinib Mesylate — DRUG
    Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible). Continue to use 28 days as a cycle, medication until disease progression (PD), intolerable toxicity occurs or the patient withdraws informed consent. However, the longest period does not exceed 24 cycles, and the treatment after 24 cycles is determined by the investigator.

Study Details

Apatinib mesylate may be an effective treatment for recurrent atypical/malignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical/malignant meningioma.

Key Dates

Start date
Aug 18, 2020
Status verified
Oct 2024
Primary completion
Aug 31, 2025
Completion
Aug 31, 2025

Study Design

Enrollment
29 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: test group

Primary Outcome Measure

PFS-6 % [ Time Frame: 6-month progression-free survival ]

Central Contacts